Skip to main content
Top
Published in: Medical Oncology 3/2012

01-09-2012 | Original Paper

ZCCHC12, a potential molecular marker of papillary thyroid carcinoma: a preliminary study

Authors: Qiu-li Li, Fu-jin Chen, Renchun Lai, Zhu-ming Guo, Rongzhen Luo, An-kui Yang

Published in: Medical Oncology | Issue 3/2012

Login to get access

Abstract

A gene expression profile analysis using an Affymetrix HG-U133 Plus 2.0 microarray with probes for 38,500 human full-length cDNAs was performed on a primary papillary thyroid carcinoma (PTC) and a nodular goiter (NG). ZCCHC12 was the gene with the most significant differential expression between PTC and NG, and this was verified using fluorescent quantitative PCR (FQ-PCR). A total of 9,485 genes were detected with a difference in transcription levels between PTC and NG. Of these, 2,098 were up-regulated with a signal log ratio (SLR) ≥ 1 and 1,714 were down-regulated with an SLR ≤ −1. Among these up-regulated and down-regulated genes, 12 genes were significantly up-regulated (SLR ≥ 5.0) and 6 genes were significantly down-regulated (SLR ≤ −5.0). The SLR of the ZCCHC12 gene was 8.8. The results of FQ-PCR showed that the medians of the log (ZCCHC12 RNA/GAPDH RNA) in PTC and NG were 0.73 and −1.68, respectively, and the difference between them was significant (P < 0.05). There were no significant correlations between the RNA levels of the ZCCHC12 gene and the clinicopathological and biochemical parameters of PTC in our pilot study. This study showed that a number of differentially expressed genes were discovered between PTC and NG. Significantly, the number of transcript copies of the ZCCHC12 gene in PTC was higher than in NG. The verified results of FQ-PCR were consistent with the microarray screening results. The ZCCHC12 gene may be a novel diagnostic molecular marker of PTC.
Literature
1.
go back to reference Singer PA, Cooper DS, Daniels GH, et al. Treatment guidelines for patients with thyroid nodules and well-differentiated thyroid cancer. Arch Intern Med. 1996;156:2165–72.PubMedCrossRef Singer PA, Cooper DS, Daniels GH, et al. Treatment guidelines for patients with thyroid nodules and well-differentiated thyroid cancer. Arch Intern Med. 1996;156:2165–72.PubMedCrossRef
2.
go back to reference Hegedüs L, Bonnema SJ, Bennedbaek FN. Management of simple nodular goiter: current status and future perspectives. Endocr Rev. 2003;24:102–32.PubMedCrossRef Hegedüs L, Bonnema SJ, Bennedbaek FN. Management of simple nodular goiter: current status and future perspectives. Endocr Rev. 2003;24:102–32.PubMedCrossRef
3.
go back to reference Tan GH, Gharib H. Thyroid incidentalomas: management approaches to nonpalpable nodules discovered incidentally on thyroid imaging. Ann Intern Med. 1997;126:226–31.PubMed Tan GH, Gharib H. Thyroid incidentalomas: management approaches to nonpalpable nodules discovered incidentally on thyroid imaging. Ann Intern Med. 1997;126:226–31.PubMed
4.
go back to reference Teng W, Shan Zh, Teng X, et al. Effect of iodine intake on thyroid diseases in China. N Engl J Med. 2006;354:2783–93.PubMedCrossRef Teng W, Shan Zh, Teng X, et al. Effect of iodine intake on thyroid diseases in China. N Engl J Med. 2006;354:2783–93.PubMedCrossRef
5.
6.
go back to reference Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:1–24.CrossRef Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:1–24.CrossRef
7.
go back to reference Hamberger B, Gharib H, Melton LJ III, et al. Fine-needle aspiration biopsy of thyroid nodules. Impact on thyroid practice and cost of care. Am J Med. 1982;73:381–4.PubMedCrossRef Hamberger B, Gharib H, Melton LJ III, et al. Fine-needle aspiration biopsy of thyroid nodules. Impact on thyroid practice and cost of care. Am J Med. 1982;73:381–4.PubMedCrossRef
8.
go back to reference Coli A, Bigotti G, Zucchetti F, et al. Galectin-3, a marker of well-differentiated thyroid carcinoma, is expressed in thyroid nodules with cytological atypia. Histopathology. 2002;40:80–7.PubMedCrossRef Coli A, Bigotti G, Zucchetti F, et al. Galectin-3, a marker of well-differentiated thyroid carcinoma, is expressed in thyroid nodules with cytological atypia. Histopathology. 2002;40:80–7.PubMedCrossRef
9.
go back to reference Martins L, Matsuo SE, Ebina KN, et al. Galectin-3 messenger ribonucleic acid and protein are expressed in benign thyroid tumors. J Clin Endocrinol Metab. 2002;87:4806–10.PubMedCrossRef Martins L, Matsuo SE, Ebina KN, et al. Galectin-3 messenger ribonucleic acid and protein are expressed in benign thyroid tumors. J Clin Endocrinol Metab. 2002;87:4806–10.PubMedCrossRef
10.
go back to reference Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949–54.PubMedCrossRef Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949–54.PubMedCrossRef
11.
go back to reference Namba H, Nakashima M, Hayashi T, et al. Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J Clin Endocrinol Metab. 2003;88:4393–7.PubMedCrossRef Namba H, Nakashima M, Hayashi T, et al. Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J Clin Endocrinol Metab. 2003;88:4393–7.PubMedCrossRef
12.
go back to reference Kimura ET, Nikiforova MN, Zhu Z, et al. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res. 2003;63:1454–7.PubMed Kimura ET, Nikiforova MN, Zhu Z, et al. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res. 2003;63:1454–7.PubMed
13.
go back to reference Cohen Y, Xing M, Mambo E, et al. BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst. 2003;95:625–7.PubMedCrossRef Cohen Y, Xing M, Mambo E, et al. BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst. 2003;95:625–7.PubMedCrossRef
14.
go back to reference Huang Y, Prasad M, Lemon WJ, et al. Gene expression in papillary thyroid carcinoma reveals highly consistent profiles. Proc Natl Acad Sci USA. 2001;98:15044–9.PubMedCrossRef Huang Y, Prasad M, Lemon WJ, et al. Gene expression in papillary thyroid carcinoma reveals highly consistent profiles. Proc Natl Acad Sci USA. 2001;98:15044–9.PubMedCrossRef
15.
go back to reference Finley DJ, Zhu B, Barden CB, et al. Discrimination of benign and malignant thyroid nodules by molecular profiling. Ann Surg. 2004;240:425–36.PubMedCrossRef Finley DJ, Zhu B, Barden CB, et al. Discrimination of benign and malignant thyroid nodules by molecular profiling. Ann Surg. 2004;240:425–36.PubMedCrossRef
16.
go back to reference Jarzab B, Wiench M, Fujarewicz K, et al. Gene expression profile of papillary thyroid cancer: sources of variability and diagnostic implications. Cancer Res. 2005;65:1587–97.PubMedCrossRef Jarzab B, Wiench M, Fujarewicz K, et al. Gene expression profile of papillary thyroid cancer: sources of variability and diagnostic implications. Cancer Res. 2005;65:1587–97.PubMedCrossRef
17.
go back to reference DeLellis RA, Lloyd RV, Heitz PU, Eng C, editors. World health organization classification of tumors, pathology and genetics of tumors of endocrine organs. Lyon: IARC Press; 2004. DeLellis RA, Lloyd RV, Heitz PU, Eng C, editors. World health organization classification of tumors, pathology and genetics of tumors of endocrine organs. Lyon: IARC Press; 2004.
18.
go back to reference Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. American Thyroid Association (ATA) guidelines taskforce on thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19:1167–214.PubMedCrossRef Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. American Thyroid Association (ATA) guidelines taskforce on thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19:1167–214.PubMedCrossRef
19.
go back to reference Mazzanti C, Zeiger MA, Costouros NG, et al. Using gene expression profiling to differentiate benign versus malignant thyroid tumors. Cancer Res. 2004;64:2898–903.PubMedCrossRef Mazzanti C, Zeiger MA, Costouros NG, et al. Using gene expression profiling to differentiate benign versus malignant thyroid tumors. Cancer Res. 2004;64:2898–903.PubMedCrossRef
20.
go back to reference Aldred MA, Huang Y, Liyanarachchi S, et al. Papillary and follicular thyroid carcinomas show distinctly different microarray expression profiles and can be distinguished by a minimum of five genes. J Clin Oncol. 2004;22:3531–9.PubMedCrossRef Aldred MA, Huang Y, Liyanarachchi S, et al. Papillary and follicular thyroid carcinomas show distinctly different microarray expression profiles and can be distinguished by a minimum of five genes. J Clin Oncol. 2004;22:3531–9.PubMedCrossRef
21.
go back to reference Finley DJ, Arora N, Zhu B, et al. Molecular profiling distinguishes papillary carcinoma from benign thyroid nodules. J Clin Endocrinol Metab. 2004;89:3214–23.PubMedCrossRef Finley DJ, Arora N, Zhu B, et al. Molecular profiling distinguishes papillary carcinoma from benign thyroid nodules. J Clin Endocrinol Metab. 2004;89:3214–23.PubMedCrossRef
22.
go back to reference Giordano TJ, Kuick R, Thomas DG, et al. Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS, and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis. Oncogene. 2005;24:6646–56.PubMedCrossRef Giordano TJ, Kuick R, Thomas DG, et al. Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS, and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis. Oncogene. 2005;24:6646–56.PubMedCrossRef
23.
go back to reference Cho G, Lim Y, Zand D, et al. Sizn1 is a novel protein that functions as a transcriptional coactivator of bone morphogenic protein signaling. Mol Cell Biol. 2008;28:1565–72.PubMedCrossRef Cho G, Lim Y, Zand D, et al. Sizn1 is a novel protein that functions as a transcriptional coactivator of bone morphogenic protein signaling. Mol Cell Biol. 2008;28:1565–72.PubMedCrossRef
24.
go back to reference Cho G, Bhat SS, Gao J, et al. Evidence that SIZN1 is a candidate X-linked mental retardation gene. Am J Med Genet A. 2008;146A:2644–50.PubMedCrossRef Cho G, Bhat SS, Gao J, et al. Evidence that SIZN1 is a candidate X-linked mental retardation gene. Am J Med Genet A. 2008;146A:2644–50.PubMedCrossRef
25.
go back to reference Cho G, Lim Y, Golden JA. SUMO interaction motifs in Sizn1 are required for promyelocytic leukemia protein nuclear body localization and for transcriptional activation. J Biol Chem. 2009;284:19592–600.PubMedCrossRef Cho G, Lim Y, Golden JA. SUMO interaction motifs in Sizn1 are required for promyelocytic leukemia protein nuclear body localization and for transcriptional activation. J Biol Chem. 2009;284:19592–600.PubMedCrossRef
26.
go back to reference Li H, Liu Q, Hu X, et al. Human ZCCHC12 activates AP-1 and CREB signaling as a transcriptional co-activator. Acta Biochim Biophys Sin (Shanghai). 2009;41:535–44.CrossRef Li H, Liu Q, Hu X, et al. Human ZCCHC12 activates AP-1 and CREB signaling as a transcriptional co-activator. Acta Biochim Biophys Sin (Shanghai). 2009;41:535–44.CrossRef
Metadata
Title
ZCCHC12, a potential molecular marker of papillary thyroid carcinoma: a preliminary study
Authors
Qiu-li Li
Fu-jin Chen
Renchun Lai
Zhu-ming Guo
Rongzhen Luo
An-kui Yang
Publication date
01-09-2012
Publisher
Springer US
Published in
Medical Oncology / Issue 3/2012
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-011-0018-6

Other articles of this Issue 3/2012

Medical Oncology 3/2012 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.